FACULTY
P. Connor Johnson, MD
Assistant Professor of Medicine
Harvard Medical School Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts
PROGRAM OVERVIEW
This activity prepares clinicians to optimize the use of CAR-T therapies for patients with DLBCL or FL by addressing barriers to access across the patient journey and identifying opportunities to streamline care through shared decision making and multidisciplinary coordination. Participants will review the therapeutic benefits and risk profiles of current and emerging CAR-T options to support individualized treatment planning and appropriate patient selection. The activity also provides practical guidance on the proactive identification, monitoring, and management of CAR-T–associated adverse events to enhance safety and improve patient outcomes.
TARGET AUDIENCE
These activities are designed to meet the educational needs of clinicians involved in the evaluation and management of patients with B-NHLs including, but not limited to, hematologists, hematologist-oncologists, oncologists, oncology nurses, and advanced practice providers (APPs; e.g., nurse practitioners, and physician assistants).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Identify barriers to CAR-T therapy access along the patient journey for individuals with DLBCL or FL and opportunities to streamline the process through shared decision making and multidisciplinary collaboration
- Describe the therapeutic benefit and risk profiles of available and emerging CAR-T therapies to inform the development of individualized treatment plans including CAR-T therapies for appropriate patients with DLBCL or FL
- Apply best practices in the proactive identification, monitoring, and treatment of CAR-T therapy-associated AEs to optimize outcomes for patients with DLBCL or FL
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| P. Connor Johnson, MD | Consulting services: AstraZeneca, ADC Therapeutics, AbbVie, Seagen, Bristol Myers Squibb, Incyte Research funding: Medically Home, Incyte, AstraZeneca |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Deborah Anderson, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Sarah Milano RN, MSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, M.S., Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: December 23, 2025
EXPIRATION DATE: December 23, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
